Application | Comment | Organism |
---|---|---|
medicine | since combination of poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase inhibition in chemotherapy does not produce increased HeLa cell death, strategies that target poly(ADP-ribose) metabolism for the improved treatment of cancer may be required to target poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase individually in order to optimize cancer cell death | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
HeLa cell | - |
Homo sapiens | - |
Synonyms | Comment | Organism |
---|---|---|
PAR glycohydrolase | - |
Homo sapiens |
PARG | - |
Homo sapiens |
General Information | Comment | Organism |
---|---|---|
malfunction | RNAi knockdown of PARG or pretreatment with 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide (ABT-888), meaning an increase in poly(ADP-ribose) level, lead to increased HeLa cell death in N-methyl-N'-nitro-N-nitrosoguanidine-treated HeLa cells. The effect can be reduced by PARP-1 inhibitors. Combination of poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase inhibition in chemotherapy does not produce increased HeLa cell death | Homo sapiens |